Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G4GY
|
|||
| Drug Name |
Anti-meso-CAR vector transduced T cells
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Endometrial cancer [ICD-11: 2C76; ICD-9: 182] | Phase 1 | [1] | |
| Malignant mesothelioma [ICD-11: 2C26.0; ICD-10: C45.9] | Phase 1 | [1] | ||
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 1 | [1] | ||
| Pancreatic cancer [ICD-11: 2C10] | Phase 1 | [1] | ||
| Triple negative breast cancer [ICD-11: 2C60-2C65] | Phase 1 | [1] | ||
| Company |
Chinese PLA General Hospital
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mesothelin (MSLN) | Target Info | CAR-T-Cell-Therapy | [1] |
| NetPath Pathway | TCR Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02580747) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.